During the past decade, IRCCS Istituto Tumori Giovanni Paolo II - U.O.C Ematologia conducted 15 clinical trials. In the 10-year time frame, 15 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 12 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "IRCCS Istituto Tumori Giovanni Paolo II - U.O.C Ematologia" #1 sponsor was "Fondazione Italiana Linfomi ONLUS" with 11 trials, followed by "Gruppo Italiano Malattie EMatologiche dell'Adulto" with 3 trials sponsored, "Janssen Pharmaceutica N.V., Belgium" with 1 trials sponsored, "Janssen-Cilag Ltd." with 1 trials sponsored and "Janssen-Cilag S.p.A." with 1 trials sponsored. Other sponsors include -5 different institutions and companies that sponsored additional 5 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "IRCCS Istituto Tumori Giovanni Paolo II - U.O.C Ematologia" #1 collaborator was "AbbVie" with 1 trials as a collaborator, "Centro di Riferimento per l'Epidemiologia e la Prev. Oncologica Piemonte" with 1 trials as a collaborator, "Janssen-Cilag S.p.A." with 1 trials as a collaborator, "Legend Biotech" with 1 trials as a collaborator and "Roche Pharma AG" with 1 trials as a collaborator. Other collaborators include -5 different institutions and companies that were collaborators in the rest 5 trials.

According to Clinical.Site data, the most researched conditions in "IRCCS Istituto Tumori Giovanni Paolo II - U.O.C Ematologia" are "ALL, Adult" (1 trials), "Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive)" (1 trials), "Acute Myeloid Leukemia With FLT3/ITD Mutation" (1 trials), "Chronic Lymphoid Leukemia" (1 trials) and "DLBCL" (1 trials). Many other conditions were trialed in "IRCCS Istituto Tumori Giovanni Paolo II - U.O.C Ematologia" in a lesser frequency.

Most popular intervention types in "IRCCS Istituto Tumori Giovanni Paolo II - U.O.C Ematologia" are "Drug" (9 trials), "Other" (3 trials), "Combination Product" (1 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Ibrutinib" (2 trials), "No intervention" (2 trials), "Rituximab" (2 trials), "ARA-C" (1 trials) and "ASCT" (1 trials). Other intervention names were less common.

The vast majority of trials in "IRCCS Istituto Tumori Giovanni Paolo II - U.O.C Ematologia" are 17 trials for "All" genders.

Currently, there are NaN active trials in "IRCCS Istituto Tumori Giovanni Paolo II - U.O.C Ematologia". 3 are not yet recruiting, 4 are recruiting, 6 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in IRCCS Istituto Tumori Giovanni Paolo II - U.O.C Ematologia, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in IRCCS Istituto Tumori Giovanni Paolo II - U.O.C Ematologia, 1 "Phase 1" clinical trials were conducted, 5 "Phase 2" clinical trials and 3 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".

IRCCS Istituto Tumori Giovanni Paolo II - U.O.C Ematologia has several departments that took part in Clinical trials: "IRCCS Oncologico Bari, Oncologia Medica" - 6 trials